Newborn Screening Market to be Worth $2.49 Billion by 2030
Meticulous Research®—a leading global market research company, published a research report titled, ‘Newborn Screening Market by Product (Consumables, Instruments) Technology (Tandem Mass Spectrometry, Pulse Oximeter, Molecular Assays, Immune Assays) Application (CHD, Infectious Diseases, Inherited & Hearing Disorders) End User – Global Forecast to 2030.’
Download
Free sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5367
According to this latest publication from Meticulous
Research®, the global newborn screening market is projected to reach $2.49
billion by 2030, at a CAGR of 7.9%. The factors driving the market are the
rising prevalence of congenital heart diseases and genetic diseases, the
increasing neonatal population, and rising awareness regarding newborn
screening. Factors such as government programs & legislation promoting
newborn screening and emerging economies are a few opportunities that would
help grow the market in the future.
Factors such as ethical concerns related to newborn
screening and the high cost of genomic newborn testing could be considered as
challenges for the newborn screening market. However, the shortage of
healthcare professionals and the emergence of non-invasive prenatal screening
technologies restrain the growth of the market.
Key Players
The key players profiled in the newborn screening
market report are Thermo Fisher Scientific, Inc. (U.S.), ARCHIMED Group
(France), PerkinElmer, Inc. (U.S.), Medtronic plc (Ireland), Trivitron
Healthcare Pvt Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.), Demant A/S
(Denmark), Baebies, Inc. (U.S.), ZenTech s.a. (Belgium), and F. Hoffmann-La
Roche AG (Switzerland).
The global newborn screening market is segmented by
Product (instruments and consumables), Technology (immune assays &
enzymatic assays, tandem mass spectrometry, molecular assays, hearing
screening technologies, pulse oximetry, and other technologies), Application
(congenital heart disease, inherited disorders {metabolic disorders, endocrine
disorders, hemoglobin disorders, and other inherited disorders}, infectious
diseases, hearing disorders, and other applications), End user (hospitals and
reference laboratories), and Geography. The study also evaluates industry
competitors and analyzes their market share at the global and regional levels.
Among products, in
2023, the consumables segment is expected to account for the largest share of
the market. The recurring demand for consumables compared to instruments, the
availability of diverse kits for newborn screening, and the increase in the
number of parents opting for newborn screening are some of the factors
supporting the largest share of this segment.
Among technologies, in 2023, the tandem mass spectrometry segment is expected to
account for the largest share of the market. The large market share of this
segment is attributed to factors such as the capability to simultaneously
screen multiple diseases, cost-effectiveness, high-throughput capability, and
rapid turnaround time.
Speak
to analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5367
Among applications, in 2023, the inherited disorders segment is expected to
account for the largest share of the market. The large market share of this
segment is attributed to the high prevalence of inherited diseases in
newborns, variations or mutations in the genes, inherited gene defects, and
abnormality in genetic composition.
Among end users, in 2023, the hospitals segment is expected to account for
the largest share of the market. The large share of the segment is attributed
to the high preference of hospitals for childbirth delivery, better
infrastructure, utilization of advanced techniques in hospitals, and the
availability of skilled professionals.
Geographic Review
This research report analyzes major geographies and
provides a comprehensive analysis of North America (U.S., Canada), Europe
(Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific
(China, Japan, India, and Rest of Asia-Pacific), Latin America and the Middle
East & Africa. In 2022, North America is expected to account for the
largest share of the newborn screening market, followed by Europe. However,
Asia Pacific is slated to register the largest CAGR during the forecast
period. The growth of this market is primarily driven by the advancing
healthcare infrastructure, supportive government initiatives, and higher birth
rates.
Quick Buy: https://www.meticulousresearch.com/Checkout/28583854
Key questions answered in the report:
·
Which are the high-growth
market segments in terms of product, technology, application, end user, and
regions/countries?
·
What was the historical market
for newborn screening across the globe?
·
What are the market forecasts
and estimates for the period 2022–2029?
·
What are the major drivers,
restraints, challenges, opportunities, and trends in the global market of
newborn screening market?
·
Who are the major players in
the global newborn screening market?
·
How is the competitive
landscape, and who are the market leaders in the global newborn screening
market?
·
What are the recent
developments in the newborn screening market?
·
What are the different
strategies adopted by the major players in the newborn screening market?
·
What are the geographical
trends and high-growth regions/countries?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment